The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 25, 2021

Filed:

Aug. 28, 2019
Applicant:

Ionis Pharmaceuticals, Inc., Carlsbad, CA (US);

Inventors:

Susan F. Murray, Poway, CA (US);

Punit P. Seth, Carlsbad, CA (US);

Michael L. McCaleb, La Jolla, CA (US);

Susan M. Freier, San Diego, CA (US);

Priyam Singh, San Diego, CA (US);

Assignee:

Other;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/11 (2006.01); A61K 48/00 (2006.01); C07H 21/02 (2006.01); C07H 21/04 (2006.01); A61K 31/713 (2006.01); A61P 27/02 (2006.01); A61K 31/475 (2006.01); A61K 31/704 (2006.01); C07K 14/705 (2006.01);
U.S. Cl.
CPC ...
A61K 31/713 (2013.01); A61K 31/475 (2013.01); A61K 31/704 (2013.01); A61P 27/02 (2018.01); C07K 14/70571 (2013.01); C12N 2310/11 (2013.01); C12N 2310/315 (2013.01); C12N 2310/322 (2013.01); C12N 2310/3231 (2013.01); C12N 2310/3341 (2013.01); C12N 2310/34 (2013.01); C12N 2310/341 (2013.01); C12N 2310/345 (2013.01); C12N 2310/346 (2013.01); C12N 2320/34 (2013.01); C12Q 2600/178 (2013.01);
Abstract

The present embodiments provide methods, compounds, and compositions for treating, preventing, ameliorating, or slowing progression of retinitis pigmentosa (RP), such as autosomal dominant retinitis pigmentosa (AdRP) by administering a P23H rhodopsin specific inhibitor to a subject. The present embodiments provided herein are directed to compounds and compositions useful for treating, preventing, ameliorating, or slowing progression of retinitis pigmentosa (RP), such as autosomal dominant retinitis pigmentosa (AdRP). In certain embodiments, P23H rhodopsin inhibitors provided herein are allele-specific antisense compounds targeted to a P23H mutant allele that are capable of selectively inhibiting expression of P23H rhodopsin mutant protein to a greater extent than wild-type protein. In certain embodiments, administration of the allele specific antisense compounds in a subject having AdRP results in selective inhibition of P23H rhodopsin and allows the normal protein produced from the wild-type allele to maintain rod survival and function in the subject.


Find Patent Forward Citations

Loading…